Considering high expression of LAG3 on CD8+ T cells, we first assessed the impact of lead-in therapy on tumor immune microenvironment changes of CD8+ T cells in relation to other immune subtypes, using a custom multiplex immunofluorescence panel (Fig. 3A, B). The gene discussed is LAG3; the disease is neoplasm.